Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Iovance Biotherapeutics Inc (IOVA)

282 + Investors. Track Smart Money conviction in IOVA. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +26
Streak
2Q ▲
Buyers last Q
65%

Smart Money Signals — IOVA

Based on 283 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added IOVA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (95% of max)

95% of all-time peak
283 hedge funds hold IOVA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
〰️

Stable — ownership unchanged year-over-year

fund count last 6Q
The number of hedge funds holding IOVA is almost the same as a year ago (-6 funds, -2% change). No significant rush to buy or sell — institutional backing is holding steady.
🟢

More buyers than sellers — 65% buying

187 buying100 selling
Last quarter: 187 funds were net buyers (66 opened a brand new position + 121 added to an existing one). Only 100 were sellers (60 trimmed + 40 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+13 vs last Q)

new funds entering per quarter
Funds opening a new IOVA position: 36 → 38 → 53 → 66. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 26% medium ■ 22% new
148 out of 283 hedge funds have held IOVA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +30% but shares only +4% — price-driven

Value
+30%
Shares
+3%
Last quarter: the total dollar value of institutional holdings rose +30%, but actual share count only changed +4%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

57 → 36 → 38 → 53 → 66 new funds/Q
New funds entering each quarter: 36 → 38 → 53 → 66. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 61% veterans vs 24% newcomers

■ 61% veterans ■ 15% 1-2yr ■ 24% new
Entry-cohort mix of 297 holders: 180 (61%) are 2+ year veterans, 46 entered 1–2 years ago, and 71 (24%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 37% AUM from major funds

37% from top-100 AUM funds
47 of 279 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.4
out of 10
Low Exit Risk
Exit risk score 3.4/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — IOVA

In 2026 Q1, 187 hedge funds were net buyers of IOVA (66 opened a new position, 121 added to an existing one), while 100 reduced or exited (60 trimmed, 40 sold completely) — a 65% buyer ratio, indicating clear institutional accumulation. Net buying has persisted for two consecutive quarters, a positive momentum signal. 37% of total institutional value in IOVA is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +26 funds (more new holders than closures). Total institutional holders: 283.

Hedge Fund Ownership: IOVA

How many hedge funds hold IOVA — quarterly history vs. share price
Quarterly hedge fund ownership of IOVA vs. share price

Market Analysis: IOVA

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: IOVA

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Iovance Biotherapeutics Inc (IOVA) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much IOVA has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
IOVA
+16.2%
XLV
+4.9%

IOVA outperformed XLV by +11.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
IOVA
+18.3%
XLV
+6.0%

Since the filing became public, IOVA outperformed XLV by +12.3% .

Interpretation: The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

29 top-rated funds 5 high-conviction
Consensus
6.4
/ 10
breadth
×
Elite
3.5
/ 10
conviction
Hedge Fund Positioning: IOVA
282 + Investors

Track Smart Money conviction in IOVA. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 282 257 9.73%
13F Shares 276M 266M 3.7%
Total Value $944M $726M 30.08%
New Positions 65 53 +12
Increased Positions 117 103 +14
Closed Positions 40 38 +2
Reduced Positions 59 60 -1
Total Calls 11 8 37.5%
Total Puts 7 6 16.67%
PUT/CALL Ratio 0.64 0.75 Bullish

Statistics: IOVA

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

282 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in IOVA. Verified SEC 13F-HR filings.

QUARTER:
Top 25 IOVA holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Mhr Fund Management LLC 7.43% 28,967,103 $101.7M
2 B Group, Inc. 3.90% 1,500,000 $5.3M
3 Palo Alto Investors LP 3.41% 6,349,563 $22.3M
4 Knott David M Jr 3.34% 1,600,000 $5.6M
5 Orion Investment Co 2.30% 2,065,652 $7.3M
6 Invenomic Capital Management LP 1.37% 8,495,551 $29.8M
7 CM Management, LLC 1.32% 450,000 $1.6M
8 Rhenman & Partners Asset Management AB 0.89% 2,055,327 $7.2M
9 Kennondale Capital Management LLC 0.81% 318,188 $1.1M
10 Parametrica Management Ltd 0.78% 195,878 $688K
11 Sector Gamma As 0.75% 900,000 $3.2M
12 Mirador Capital Partners LP 0.53% 1,073,236 $3.8M
13 Scientech Research LLC 0.40% 138,148 $485K
14 Virtus Investment Advisers, LLC 0.37% 383,763 $1.3M
15 Rice Hall James & Associates, LLC 0.30% 1,514,907 $5.3M
16 Sugar Maple Asset Management, LLC 0.26% 120,000 $421K
17 Long Focus Capital Management, LLC 0.19% 2,100,000 $7.4M
18 Haven Capital Group, Inc. 0.19% 59,143 $208K
19 Corsair Capital Management, L.P. 0.18% 350,000 $1.2M
20 Diadema Partners LP 0.18% 300,000 $1.1M
21 QVT Financial LP 0.17% 678,564 $2.4M
22 Portland Investment Counsel INC. 0.15% 130,000 $456K
23 Monaco Asset Management SAM 0.15% 225,000 $790K
24 Soleus Capital Management, L.P. 0.14% 1,000,000 $3.5M
25 Oxford Asset Management LLP 0.12% 80,776 $284K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Iovance Biotherapeutics Inc (IOVA)

What does the Smart Money Trend signal show for IOVA?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added IOVA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for IOVA?

More buyers than sellers — 65% buying: Last quarter: 187 funds were net buyers (66 opened a brand new position + 121 added to an existing one). Only 100 were sellers (60 trimmed + 40 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for IOVA holders?

Strong quality — 37% AUM from major funds: 47 of 279 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held IOVA?

52% of holders stayed for 2+ years: 148 out of 283 hedge funds have held IOVA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Iovance Biotherapeutics Inc (IOVA) following the 2026 Q1 hedge fund 13F filings?

As of today, IOVA has moved +18.3% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of +12.3%. Since the quarter end (March 31, 2026), IOVA has gained +16.2% vs +4.9% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →